Clinical and demographic details of 1135 AML patients in total cohort
. | Total . | FLT3/ITD- (% total ITD-) . | FLT3/ITD+ (% total ITD+) . | % FLT3/ITD+ . | P . |
|---|---|---|---|---|---|
| Total | 1135 | 852 | 283 | 25 | — |
| AML10 | 428 | 329 (39) | 99 (35) | 23 | .3 |
| AML12 | 707 | 523 (61) | 184 (65) | 26 | — |
| De novo | 1042 | 778 (91) | 264 (93) | 25 | .5 |
| Secondary | 92 | 73 (9) | 19 (7) | 21 | — |
| Unknown | 1 | 1 | 0 | 0 | — |
| FAB type | .001 | ||||
| M0 | 36 | 34 (4) | 2 (1) | 6 | |
| M1 | 222 | 159 (20) | 63 (23) | 28 | |
| M2 | 343 | 264 (33) | 79 (29) | 23 | |
| M4 | 278 | 194 (24) | 84 (31) | 30 | |
| M5 | 128 | 91 (11) | 37 (14) | 29 | |
| M6 | 32 | 29 (4) | 3 (1) | 9 | |
| M7 | 16 | 15 (2) | 1 (< 0.5) | 6 | |
| RAEB-t | 20 | 18 (2) | 2 (1) | 10 | |
| Bilineage | 1 | 0 | 1 (< 0.5) | 100 | |
| Other | 1 | 1 (< 0.5) | 0 | 0 | |
| Unknown | 58 | 47 | 11 | 19 | |
| Sex | .4 | ||||
| Male | 568 | 432 (51) | 136 (48) | 24 | |
| Female | 567 | 420 (49) | 147 (52) | 26 | |
| Age, y | .14 | ||||
| 15-29 | 230 | 179 (21) | 51 (18) | 22 | |
| 30-39 | 248 | 188 (22) | 60 (21) | 24 | |
| 40-49 | 333 | 247 (29) | 86 (30) | 26 | |
| 50-59 | 305 | 228 (27) | 77 (27) | 25 | |
| 60 or older | 19 | 10 (1) | 9 (3) | 47 | |
| Median | 42 | 42 | 43 | — | |
| WBC, × 109/L | < .001 | ||||
| Less than 10 | 358 | 318 (38) | 40 (14) | 11 | |
| 10-19.9 | 181 | 141 (17) | 40 (14) | 22 | |
| 20-49.9 | 238 | 177 (21) | 61 (22) | 26 | |
| 50-99.9 | 169 | 109 (13) | 60 (21) | 36 | |
| 100 or above | 168 | 89 (11) | 79 (28) | 47 | |
| Unknown | 21 | 18 | 3 | 14 | |
| Median | 21 | 16 | 50 | — | |
| Cytogenetics | < .001 | ||||
| Favorable | 151 | 134 (19) | 17 (8) | 11 | |
| Intermediate | 655 | 455 (65) | 200 (89) | 31 | |
| Adverse | 116 | 108 (15) | 8 (4) | 7 | |
| Unknown | 213 | 155 | 58 | 27 |
. | Total . | FLT3/ITD- (% total ITD-) . | FLT3/ITD+ (% total ITD+) . | % FLT3/ITD+ . | P . |
|---|---|---|---|---|---|
| Total | 1135 | 852 | 283 | 25 | — |
| AML10 | 428 | 329 (39) | 99 (35) | 23 | .3 |
| AML12 | 707 | 523 (61) | 184 (65) | 26 | — |
| De novo | 1042 | 778 (91) | 264 (93) | 25 | .5 |
| Secondary | 92 | 73 (9) | 19 (7) | 21 | — |
| Unknown | 1 | 1 | 0 | 0 | — |
| FAB type | .001 | ||||
| M0 | 36 | 34 (4) | 2 (1) | 6 | |
| M1 | 222 | 159 (20) | 63 (23) | 28 | |
| M2 | 343 | 264 (33) | 79 (29) | 23 | |
| M4 | 278 | 194 (24) | 84 (31) | 30 | |
| M5 | 128 | 91 (11) | 37 (14) | 29 | |
| M6 | 32 | 29 (4) | 3 (1) | 9 | |
| M7 | 16 | 15 (2) | 1 (< 0.5) | 6 | |
| RAEB-t | 20 | 18 (2) | 2 (1) | 10 | |
| Bilineage | 1 | 0 | 1 (< 0.5) | 100 | |
| Other | 1 | 1 (< 0.5) | 0 | 0 | |
| Unknown | 58 | 47 | 11 | 19 | |
| Sex | .4 | ||||
| Male | 568 | 432 (51) | 136 (48) | 24 | |
| Female | 567 | 420 (49) | 147 (52) | 26 | |
| Age, y | .14 | ||||
| 15-29 | 230 | 179 (21) | 51 (18) | 22 | |
| 30-39 | 248 | 188 (22) | 60 (21) | 24 | |
| 40-49 | 333 | 247 (29) | 86 (30) | 26 | |
| 50-59 | 305 | 228 (27) | 77 (27) | 25 | |
| 60 or older | 19 | 10 (1) | 9 (3) | 47 | |
| Median | 42 | 42 | 43 | — | |
| WBC, × 109/L | < .001 | ||||
| Less than 10 | 358 | 318 (38) | 40 (14) | 11 | |
| 10-19.9 | 181 | 141 (17) | 40 (14) | 22 | |
| 20-49.9 | 238 | 177 (21) | 61 (22) | 26 | |
| 50-99.9 | 169 | 109 (13) | 60 (21) | 36 | |
| 100 or above | 168 | 89 (11) | 79 (28) | 47 | |
| Unknown | 21 | 18 | 3 | 14 | |
| Median | 21 | 16 | 50 | — | |
| Cytogenetics | < .001 | ||||
| Favorable | 151 | 134 (19) | 17 (8) | 11 | |
| Intermediate | 655 | 455 (65) | 200 (89) | 31 | |
| Adverse | 116 | 108 (15) | 8 (4) | 7 | |
| Unknown | 213 | 155 | 58 | 27 |
P values are for Mantel-Haenszel test for trend in age and WBC count and for chi-square test for heterogeneity elsewhere.
FAB indicates French-American-British; RAEB-t, refractory anemia with excess of blasts in transformation; WBC, white blood cell count; and —, not applicable.